European journal of neurology : the official journal of the European Federation of Neurological Societies
-
Randomized Controlled Trial
A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
To assess the efficacy and safety of olesoxime, a molecule with neuroprotective properties, in patients with amyotrophic lateral sclerosis (ALS) treated with riluzole. ⋯ Olesoxime, although well tolerated, did not show a significant beneficial effect in ALS patients treated with riluzole.